Media

Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results

Oncopeptides – Invitation to presentation of the year-end report 2023

Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy

BONESUPPORT HOLDING AB (publ) – Publishes year end report 2023

Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan

BONESUPPORT HOLDING AB (publ) – INVITATION TO CONFERENCE CALL AND WEBCAST FOR YEAR-END REPORT 2023

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy